Publications database

Displaying 1 - 3 of 3

Cover of the risk assessment of MDMB 4en PINACA

Report on the risk assessment of a new psychoactive substance: methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

This publication presents the data and findings of the risk assessment on methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 9 December 2020. On the basis...

Publication cover

New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic — an update from the EU Early Warning System

In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning...

EMCDDA initial report on the new psychoactive substance MDMB-4en-PINACA

Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) is a synthetic cannabinoid receptor agonist. Similar to other synthetic cannabinoids, it is sold as a ‘legal’ replacement for cannabis and controlled synthetic cannabinoids. Because of their high potency...